NERCe002-A-3

chHES-90-pINDUCER20-tet-14-3-3ζ

General#

Cell Line

hPSCreg Name NERCe002-A-3
Alternative name(s)
chHES-90-pINDUCER20-tet-14-3-3ζ
Cell line type Human embryonic stem cell (hESC)
Last update 22nd May 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator National Engineering and Research Center of Human Stem Cell (NERC)

External Databases

BioSamples SAMEA104132874
Cellosaurus CVCL_VF81

General Information

Publications
* Is the cell line readily obtainable for third parties?
No
Subclone of

Donor Information#

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes

External Databases (Donor)

BioSamples SAMEA104132870

Ethics#

Also have a look at the ethics information for the parental line NERCe002-A .
Was the embryo established purely for research purposes? Yes
Have both parents consented to the use of the embryo for ESC derivation? Yes
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Alternatives to consent are available? Yes
Alternatives to consent
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? the ethical committee of Reproductive and Genetic Hospital of CITIC-Xiangya
Approval number 2001-01

hESC Derivation#

Date of derivation 2015-05-22
Supernumerary embryos from IVF treatment?
Yes
Separation of research and IVF treatment?
Yes
PGD Embryo?
No

Culture Conditions#

Feeder cells human
Passage method Mechanically
O2 Concentration 5 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: D/F 12
Main protein source: Knock-out serum replacement
Serum concentration: 15 %
Supplements
L-Glutamine %
NEAA
bFGF

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Alkaline Phosphatase
Yes
NANOG
Yes
Self-renewal
Positive
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro directed differentiation
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XY

Other Genotyping (Cell Line)

Genetic Modification#

Genetic modifications not related to a disease
14-3-3ζ (target)
Transgene expression
Viral
Lentivirus